MDElliottMD: home-claude category backfill (parser-claude gap closure)

2026-05-23T10:43:37Z

home-claude category backfill (parser-claude gap closure)

← Older revision		Revision as of 10:43, 23 May 2026
Line 21:		Line 21:
	== References ==		== References ==
	<references />		<references />
			[[Category:Antigout agents]]
			[[Category:Anti-inflammatories]]
			[[Category:Microtubule inhibitors]]

MDElliottMD: parser-claude batch MedTemplate pre-fill, Top 300 #215

2026-05-23T04:00:15Z

parser-claude batch MedTemplate pre-fill, Top 300 #215

New page

{{MedTemplate
| generic = Colchicine
| brand = Colcrys, Mitigare, Gloperba, Lodoco (low-dose cardiovascular)
| structure =
| classes = [[:Category:Antigout_agents|Antigout agent]], [[:Category:Anti-inflammatories|Anti-inflammatory]], [[:Category:Microtubule_inhibitors|Microtubule inhibitor]]
| uses = <vote slug="acute-gout-flare-use">Acute gout flare (early treatment)</vote>, <vote slug="gout-prophylaxis-use">Gout flare prophylaxis (when initiating urate-lowering therapy)</vote>, <vote slug="familial-mediterranean-fever-use">Familial Mediterranean fever</vote>, <vote slug="recurrent-pericarditis-use">Recurrent pericarditis</vote>, <vote slug="atherosclerotic-cv-low-dose-use">Atherosclerotic cardiovascular risk reduction (low-dose, post-LoDoCo trials)</vote>
| starting_dose = Acute gout: 1.2 mg PO at first symptom, then 0.6 mg 1 hour later (total 1.8 mg in 1 hour, the FDA-revised regimen); prophylaxis 0.6 mg PO daily or BID; FMF 1-2 mg/d; pericarditis 0.5-0.6 mg BID for 3 months; Lodoco 0.5 mg PO daily for CV risk reduction
| preparations = 0.6 mg tablets; 0.6 mg/5 mL solution; 0.5 mg tablets (Lodoco)
| fda_max = 1.8 mg in any 1-hour period (acute gout); 1.2 mg/d (prophylaxis with renal/hepatic impairment); much lower with strong CYP3A4 or P-gp inhibitors
| pill_id =
| routes = Oral (IV form withdrawn US 2009 due to fatal toxicity reports)
| onset = Anti-inflammatory effect within 24 hours of gout flare onset; loses effectiveness if delayed
| duration = Hours per dose
| halflife = ~27-31 hours; markedly prolonged in renal/hepatic impairment and with CYP3A4 or P-gp inhibitors<ref name="colcrys-label">FDA Prescribing Information, Colcrys (colchicine), Takeda, current revision. https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/022351s011s012lbl.pdf</ref>
| bioavailability = ~45% (oral)<ref name="colcrys-label" />
| pregnancy = Used in FMF in pregnancy; otherwise weigh against alternatives.{{citation needed}}
| legal = [[USLegal:Prescription only|Rx-only]] in US
| mechanism = <vote slug="colchicine-mech-claim">Colchicine binds tubulin and prevents microtubule polymerization, disrupting neutrophil migration, NLRP3 inflammasome assembly, and IL-1β release — the proximal drivers of MSU-crystal-induced gout inflammation.</vote> Narrow therapeutic window with no antidote; '''fatal interactions''' with strong CYP3A4 or P-glycoprotein inhibitors (clarithromycin, certain calcineurin inhibitors, ritonavir) including in patients with renal/hepatic impairment. Symptoms of overdose include severe GI then multi-organ failure with delayed bone marrow suppression<ref name="colcrys-label" />.
}}

== References ==
<references />

Colchicine - Revision history

MDElliottMD: home-claude category backfill (parser-claude gap closure)

MDElliottMD: parser-claude batch MedTemplate pre-fill, Top 300 #215